Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis
Top Cited Papers
Open Access
- 8 January 2016
- journal article
- practice guideline
- Published by Wiley in Arthritis & Rheumatology
- Vol. 68 (5), 1060-1071
- https://doi.org/10.1002/art.39573
Abstract
Objective To update the 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations for the spectrum of manifestations affecting patients with psoriatic arthritis (PsA). Methods GRAPPA rheumatologists, dermatologists, and PsA patients drafted overarching principles for the management of PsA, based on consensus achieved at face‐to‐face meetings and via online surveys. We conducted literature reviews regarding treatment for the key domains of PsA (arthritis, spondylitis, enthesitis, dactylitis, skin disease, and nail disease) and convened a new group to identify pertinent comorbidities and their effect on treatment. Finally, we drafted treatment recommendations for each of the clinical manifestations and assessed the level of agreement for the overarching principles and treatment recommendations among GRAPPA members, using an online questionnaire. Results Six overarching principles had ≥80% agreement among both health care professionals (n = 135) and patient research partners (n = 10). We developed treatment recommendations and a schema incorporating these principles for arthritis, spondylitis, enthesitis, dactylitis, skin disease, nail disease, and comorbidities in the setting of PsA, using the Grading of Recommendations, Assessment, Development and Evaluation process. Agreement of >80% was reached for approval of the individual recommendations and the overall schema. Conclusion We present overarching principles and updated treatment recommendations for the key manifestations of PsA, including related comorbidities, based on a literature review and consensus of GRAPPA members (rheumatologists, dermatologists, other health care providers, and patient research partners). Further updates are anticipated as the therapeutic landscape in PsA evolves.Keywords
Funding Information
- Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
- Pharmaceutical companies, currently AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, with Covagen and Crescendo as Innovation Partners
This publication has 31 references indexed in Scilit:
- Treatments for Nail Psoriasis: A Systematic Review by the GRAPPA Nail Psoriasis Work GroupThe Journal of Rheumatology, 2014
- Safety and Efficacy of Therapies for Skin Symptoms of Psoriasis in Patients with Psoriatic Arthritis: A Systematic ReviewThe Journal of Rheumatology, 2014
- Comprehensive Treatment of Dactylitis in Psoriatic ArthritisThe Journal of Rheumatology, 2014
- Systematic Review of Treatment Effectiveness and Outcome Measures for Enthesitis in Psoriatic ArthritisThe Journal of Rheumatology, 2014
- Updated Guidelines for the Management of Axial Disease in Psoriatic ArthritisThe Journal of Rheumatology, 2014
- Drug Therapies for Peripheral Joint Disease in Psoriatic Arthritis: A Systematic ReviewThe Journal of Rheumatology, 2014
- Systematic Review of Treatments for Psoriatic Arthritis: 2014 Update for the GRAPPAThe Journal of Rheumatology, 2014
- Treatment recommendations for psoriatic arthritisAnnals Of The Rheumatic Diseases, 2008
- Classification criteria for psoriatic arthritis: Development of new criteria from a large international studyArthritis & Rheumatism, 2006
- PSORIATIC ARTHRITISRheumatic Disease Clinics of North America, 1998